Guardant Health, Inc. (GH) Stock Analysis & Investment Frameworks
Guardant Health, Inc. (GH) stock analysis on Invetso. Review Guardant Health, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Guardant Health, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
Guardant Health, Inc. Key Financial Metrics
- Market Cap: $22.62B
- Revenue: $982.02M
- ROE: 211.46%
- ROIC: -29.30%
- Dividend Yield: N/A
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Guardant Health, Inc. Investment Frameworks
Invetso analyzes Guardant Health, Inc. (GH) across the following frameworks:
- Guardant Health, Inc. 10Y Growth Potential
- Guardant Health, Inc. Scenario Analysis
- Guardant Health, Inc. Risks & Opportunities
- Guardant Health, Inc. Economic Moat
- Guardant Health, Inc. Business Model
- Guardant Health, Inc. Management
- Guardant Health, Inc. SWOT Analysis
- Guardant Health, Inc. Porter's 5 Forces
- Guardant Health, Inc. PESTLE Analysis
- Guardant Health, Inc. ESG Analysis